Recent animal studies of NASH have supported these findings by demonstrating improvements in hepatic steatosis following GLP-1 therapy [10], [11], [12], [13], which in some cases was accompanied by reductions in oxidative stress [11], [14], [15] and fibrosis [16]. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.